Japan's top drugmaker appoints first foreign boss

Japan's top drugmaker said Saturday it had picked a GlaxoSmithKline executive as its next president in a rare example of overseas head-hunting by a major Japanese firm.

The board of directors at Takeda Pharmaceutical, which has been active in foreign acquisitions in recent years, approved 47-year-old French Christophe Weber, as and candidate as the next chief executive.

He will be the first non-Japanese chief in 230 years of history at the company based in western Japan's Osaka.

Weber will join Takeda to take the role of chief operating officer by April 2014 and is expected to become president upon approval at a general meeting of shareholders in June, Takeda said in a statement.

Current president and chief executive Yasuchika Hasegawa is expected to become chairman and chief executive.

"We have extremely high expectations for Mr Weber's contributions to further enhance and accelerate the implementation of Takeda's global strategy," Hasegawa said in the statement.

Weber, educated at the University of Lyon, has held various positions at GSK in Europe, United States and the Asia-Pacific region.

Takeda operates in more than 70 countries after its 2011 acquisition of major Swiss rival Nycomed for $14 billion.

There are only a handful of foreign chiefs at leading Japanese companies. Carlos Ghosn, the of French auto group Renault who also heads Nissan Motor, is one of the most prominent.

add to favorites email to friend print save as pdf

Related Stories

Japanese firm buys US pharmaceutical company

Oct 05, 2012

(AP)—A Japanese pharmaceutical company is acquiring LigoCyte Pharmaceuticals in a $60 million deal to expand its vaccine division, Takeda Pharmaceutical Co. announced.

US drug firm Mylan to buy Indian firm for $1.6 bn

Feb 27, 2013

US generic drugs specialist Mylan said Thursday it would buy a unit of India's pharma firm Strides Arcolab for $1.6 billion, boosting its presence in the high-growth injectable drugs market.

Recommended for you

Novartis Japan admits concealing drug side effects

22 hours ago

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

Expression of privilege in vaccine refusal

Aug 27, 2014

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

User comments